Cellectis SA (NASDAQ:CLLS) – Analysts at Oppenheimer issued their FY2023 earnings per share (EPS) estimates for Cellectis in a note issued to investors on Tuesday, March 12th. Oppenheimer analyst H. Singh expects that the biotechnology company will earn $3.68 per share for the year. Oppenheimer currently has a “Buy” rating and a $44.00 target price on the stock.

Several other equities analysts have also issued reports on the stock. BidaskClub raised shares of Cellectis from a “sell” rating to a “hold” rating in a report on Saturday. William Blair assumed coverage on shares of Cellectis in a report on Wednesday. They issued an “outperform” rating on the stock. Barclays reaffirmed a “buy” rating and issued a $50.00 price target on shares of Cellectis in a report on Wednesday. Citigroup cut their price target on shares of Cellectis from $37.00 to $22.00 and set a “neutral” rating on the stock in a report on Monday, March 11th. Finally, ValuEngine lowered shares of Cellectis from a “hold” rating to a “sell” rating in a report on Thursday, January 24th. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $32.00.

NASDAQ CLLS opened at $19.31 on Friday. Cellectis has a 12-month low of $15.34 and a 12-month high of $38.85. The firm has a market capitalization of $792.48 million, a price-to-earnings ratio of -10.01 and a beta of 1.76.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in Cellectis by 13.8% in the third quarter. BlackRock Inc. now owns 504,948 shares of the biotechnology company’s stock worth $14,250,000 after purchasing an additional 61,235 shares during the last quarter. Morgan Stanley grew its holdings in Cellectis by 25.2% in the third quarter. Morgan Stanley now owns 481,450 shares of the biotechnology company’s stock worth $13,586,000 after purchasing an additional 96,847 shares during the last quarter. Sphera Funds Management LTD. grew its holdings in Cellectis by 27.3% in the third quarter. Sphera Funds Management LTD. now owns 447,970 shares of the biotechnology company’s stock worth $12,642,000 after purchasing an additional 96,096 shares during the last quarter. Credit Suisse AG grew its holdings in Cellectis by 9.2% in the third quarter. Credit Suisse AG now owns 420,667 shares of the biotechnology company’s stock worth $11,871,000 after purchasing an additional 35,363 shares during the last quarter. Finally, Macquarie Group Ltd. lifted its stake in shares of Cellectis by 15.0% during the fourth quarter. Macquarie Group Ltd. now owns 219,675 shares of the biotechnology company’s stock worth $3,658,000 after buying an additional 28,688 shares during the period. 27.62% of the stock is currently owned by institutional investors and hedge funds.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).

Featured Article: No Load Funds

Earnings History and Estimates for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.